Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) AI Stock Analysis

• Market Cap: AU$506.31M
• Dividend Yield: N/A
• Average Volume (3M): 287.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: -8.99%
• EPS Growth: -18.16%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 320,947,020
• 10 Day Avg. Volume: 240,875
• 30 Day Avg. Volume: 287,535
• PEG Ratio: 0.89
• Price to Book (P/B): -25.56
• Price to Sales (P/S): 196.53
• P/FCF Ratio: -12.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$2.18
• Price Target Upside: 32.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$1.50 ▼(-8.54% Downside)

Imricor Medical Systems' overall stock score is primarily impacted by its poor financial performance, characterized by negative margins and high leverage. Technical analysis provides some neutral signals, but the negative valuation metrics further weigh down the score.

Positive Factors

Innovative Product Line

The focus on MRI-compatible devices positions Imricor as a leader in enhancing cardiac procedure safety and efficiency, providing a competitive edge in the medical technology industry.

Strategic Partnerships

Collaborations with healthcare providers and research institutions enhance product offerings and market penetration, supporting long-term revenue growth.

Revenue Growth

Consistent revenue growth over the years indicates expanding market adoption and potential for future sales increases, despite current profitability challenges.

Negative Factors

Negative Profit Margins

Deeply negative profit margins highlight significant cost management issues, impacting the company's ability to achieve profitability and sustain operations.

High Leverage

High leverage and negative equity indicate financial instability, posing risks to solvency and limiting the company's ability to invest in growth opportunities.

Cash Flow Challenges

Persistent cash burn and negative cash flows suggest operational inefficiencies and challenges in generating cash from core operations, threatening long-term viability.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model

Company Description

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

How the Company Makes Money

Imricor generates revenue primarily through the sale of its MRI-compatible medical devices and related software solutions. The company operates a business model that includes direct sales to hospitals and clinics, as well as partnerships with medical device distributors and healthcare providers. Key revenue streams include the sale of its catheter systems, which are used in electrophysiological studies and ablation procedures, and recurring revenue from software licensing and servicing agreements. Additionally, strategic partnerships with healthcare organizations and research institutions help to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview

Summary

Imricor Medical Systems faces significant financial challenges. Despite revenue growth, the company struggles with deeply negative profit margins, high leverage, and negative equity, indicating solvency risks. Persistent cash burn and negative cash flows highlight operational inefficiencies.

Income Statement

Imricor Medical Systems has shown consistent revenue growth, increasing from $639,704 in 2019 to $959,424 in 2024. However, the company has been struggling with negative gross and net profit margins. The gross profit margin has been negative each year, with the most recent year at -96.32%, and the net profit margin has consistently been deeply negative, reaching -3094.85% in 2024. This indicates significant challenges in profitability and cost management. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a worrisome trend with negative stockholders' equity of -$7,377,033 in 2024, indicating potential solvency risks. The debt-to-equity ratio is not meaningful due to negative equity, and while the total assets have increased over time, the leverage is high with total liabilities surpassing total assets. The equity ratio is also negative due to negative equity, highlighting financial instability.

Cash Flow

Imricor's cash flow situation is concerning, with a continuous negative operating cash flow and free cash flow, indicating cash burn. The free cash flow has been negative, reaching -$15,651,886 in 2024. Despite a positive financing cash flow from capital raises, the operating cash flow to net income ratio is negative, suggesting operating inefficiencies and challenges in generating cash from core operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	650.11K	959.42K	615.57K	816.01K	696.27K	702.16K
Gross Profit	-691.43K	-924.12K	-1.12M	-1.53M	-1.90M	-397.67K
EBITDA	-13.23M	-15.55M	-21.87M	-16.47M	-19.57M	-11.43M
Net Income	-29.41M	-29.69M	-22.63M	-17.53M	-20.56M	-13.08M
Balance Sheet
Total Assets	55.57M	21.62M	8.31M	13.70M	26.86M	33.57M
Cash, Cash Equivalents and Short-Term Investments	50.34M	15.71M	831.52K	5.69M	18.52M	25.14M
Total Debt	24.81M	21.35M	10.42M	4.45M	1.74M	1.39M
Total Liabilities	32.49M	29.00M	17.06M	6.19M	4.46M	4.75M
Stockholders Equity	23.08M	-7.38M	-12.83M	7.51M	22.40M	28.82M
Cash Flow
Free Cash Flow	-12.27M	-15.65M	-13.06M	-17.06M	-18.11M	-12.97M
Operating Cash Flow	-12.12M	-15.57M	-12.98M	-16.82M	-17.49M	-12.23M
Investing Cash Flow	-157.60K	-74.98K	-82.78K	-238.86K	-695.30K	-774.03K
Financing Cash Flow	32.21M	30.33M	8.21M	3.94M	11.59M	33.02M

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Positive. The current price of 1.64 is above the 20-day moving average (MA) of 1.47, above the 50-day MA of 1.44, and above the 200-day MA of 1.47, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 48.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMR.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYC	50 Neutral	AU$104.47M	-7.78	-31.98%	―	34.20%	-23.90%
IPD	48 Neutral	AU$69.30M	-2.96	-74.00%	―	23.31%	-17.35%
IMR	44 Neutral	AU$506.31M	-7.31	-432.03%	―	-8.99%	-18.16%
EMV	44 Neutral	AU$171.94M	-16.13	-70.55%	―	―	-257.32%
HMD	43 Neutral	AU$42.81M	-7.69	-513.22%	―	-34.06%	75.47%
MX1	41 Neutral	AU$63.70M	-3.89	-128.19%	―	-14.25%	-22.83%

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events

Imricor Adds Charité as Second Global Site for VISABL-VT MRI-Guided Ablation Trial

Imricor Medical Systems has announced that Charité University Hospital in Berlin, one of the world’s leading hospitals, will become the second site globally to join the company’s VISABL-VT clinical trial, which is aimed at advancing real-time MRI-guided ablation for ventricular tachycardia. Following software upgrades to Charité’s Philips MRI system to integrate Imricor’s NorthStar mapping platform and the removal of now-commercial CE-marked Imricor devices from the investigational study framework, the trial protocol has been simplified, and Charité’s electrophysiology team plans to begin commercial atrial flutter ablations in the MRI lab from the first quarter of 2026, underscoring Imricor’s strengthening clinical footprint and its strategic collaboration with Philips in MRI-guided electrophysiology.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Expands VISABL-AFL Clinical Trial to UVA Health

Imricor Medical Systems has announced that the University of Virginia Health Medical Center will become the second US site for its VISABL-AFL clinical trial, following IRB approval. This development marks a significant step in Imricor’s efforts to enhance MRI-guided electrophysiology ablations, with procedures expected to begin in February. The expansion to UVA Health is part of a broader strategy to ensure timely enrolment and FDA processes, positioning Imricor to strengthen its market presence and impact in the field of interventional cardiology.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Achieves Milestone with First MRI-Guided VT Ablation

Imricor Medical Systems, Inc. announced a significant milestone in the field of MRI-guided electrophysiology with the successful completion of the first ischemic ventricular tachycardia (VT) ablation performed entirely under real-time MRI guidance. This groundbreaking procedure, conducted at Amsterdam University Medical Centre, marks a critical advancement in treating complex arrhythmias and demonstrates the potential for safer and more effective ablations, even in high-risk patients with implantable cardioverter defibrillators. The achievement is expected to drive increased demand for Imricor’s technology and accelerate its adoption across Europe, as additional sites are set to join the VISABL-VT clinical trial.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Expands CDI Issuance to Strengthen Market Position

Imricor Medical Systems, Inc. announced the issuance of 144,526 CHESS Depositary Interests (CDIs) following the exercise of existing options, with these securities to rank equally with existing shares. This move is part of Imricor’s strategy to leverage section 708A of the Corporations Act for the sale of CDIs without disclosure to investors, reflecting the company’s compliance with relevant regulations and its ongoing efforts to enhance its market position and operational capabilities.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Announces Quotation of New Securities on ASX

Imricor Medical Systems, Inc. has announced the application for quotation of 144,526 securities on the Australian Securities Exchange (ASX), effective October 24, 2025. This move could potentially enhance the company’s capital structure and market presence, offering opportunities for growth and increased investor engagement.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Advances MRI-Guided Cardiac Ablation with Key Regulatory and Commercial Milestones

Imricor Medical Systems, Inc. has achieved significant milestones in its operations, including the submission of 510(k) approvals for its NorthStar and Vision-MR Diagnostic Catheter with the FDA, and the commercial launch of NorthStar in Europe following CE Mark approval. The company is expanding its clinical trial footprint and driving adoption of its MRI-guided electrophysiology products, with a growing European pipeline and discussions with US hospitals revealing a larger-than-expected installed base of cardiology-controlled MRI scanners. Financially, Imricor reported operating cash outflows of US$4.8 million for Q3 2025, with a cash balance of US$38.3 million and US$7.5 million in short-term investments, as it continues to focus on expanding its market presence and transforming cardiac ablation procedures worldwide.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Aims for Global Expansion of iCMR Technology

Imricor Medical Systems, Inc. has presented at the Canaccord Drug & Device Conference, highlighting its vision to expand the use of iCMR technology globally. This strategic move aims to enhance its market positioning by leveraging its unique MRI-compatible products, potentially impacting stakeholders by broadening the adoption of advanced cardiac procedures.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Achieves World-First MRI-Guided PFA Ablation

Imricor Medical Systems, Inc. has announced a groundbreaking achievement by performing the world’s first Pulsed Field Ablation (PFA) under real-time MRI guidance in an iCMR lab. This advancement marks a significant milestone in Imricor’s PFA development program, demonstrating the flexibility and adaptability of their platform. The procedure, conducted using the second-generation Vision-MR Ablation Catheter, validates Imricor’s proprietary technology for integrating PFA energy with real-time MRI visualization. This innovation positions Imricor to meet the evolving needs of electrophysiologists globally and underscores the company’s commitment to advancing MRI-guided electrophysiology procedures.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.06 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Announces Cessation of Securities

Imricor Medical Systems, Inc. announced the cessation of 3,750 securities due to the expiry of options or other convertible securities without exercise or conversion as of October 1, 2025. This cessation could impact the company’s financial structure and stakeholder interests, reflecting a strategic adjustment in its capital management.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Issues New Equity Securities for Employee Incentive

Imricor Medical Systems, Inc. announced the issuance of 30,000 unquoted equity securities as part of an employee incentive scheme. This strategic move is likely to strengthen employee engagement and align interests with the company’s growth objectives, potentially enhancing its competitive position in the medical technology sector.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.